These findings support the pathogenetic role of the classical RAS axis (ACE-Ang II-AT1R) in PAH progression and emphasize the therapeutic potential of strategies focused on reestablishing balance to the alternative axis (ACE2-Ang-(1–7)-MAS/AT2R), such as FF treatment. The gene discussed is ACE2; the disease is pulmonary arterial hypertension.